Day One Biopharmaceuticals Bilan de santé
Santé financière contrôle des critères 5/6
Day One Biopharmaceuticals possède un total de capitaux propres de $555.5M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $600.8M et de $45.3M.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$558.38m |
| Fonds propres | US$555.46m |
| Total du passif | US$45.34m |
| Total des actifs | US$600.81m |
Mises à jour récentes de la santé financière
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12
We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Recent updates
Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically
Nov 04We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Analyse de la situation financière
Passif à court terme: Les actifs à court terme de DAWN ( $581.0M ) dépassent ses passifs à court terme ( $39.7M ).
Passif à long terme: Les actifs à court terme de DAWN ( $581.0M ) dépassent ses passifs à long terme ( $5.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: DAWN est sans dette.
Réduire la dette: DAWN n'a eu aucune dette au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: DAWN dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: Données insuffisantes pour déterminer si DAWN dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.